Cancer Therapies
The Cancer Development Laboratory, established in mid-2007, aims to
identify which of the molecular targets discovered by Garvan's cancer
researchers hold promise for new cancer therapies.
Biotech and pharmaceutical companies are constantly alert for molecular targets in their quest to develop new drugs. Drug development is very costly, however, and companies first need some validation of targets. Strong evidence that blocking the expression or function of certain molecular targets reduces tumour growth and/or metastasis in cell culture and in animal models is needed to support drug development initiatives. Our focus is on analysis of cell surface targets for monoclonal antibody therapeutics and on intracellular targets for small molecule inhibitor drugs.
We work closely with Garvan's Business Development Unit to identify potential commercial partners and to set up collaborative and/or licensing agreements.
Staff
Dr Hilary Brooks |
Lisa-Jane Graham |
